Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Sahu, Ram Kumar ^a   Yadav, Rajni ^a   Prasad, Pushpa ^a   Roy, Amit ^a   Chandrakar, Shashikant ^a  

^a Department of Pharmaceutical Analysis and Quality Assurance   (India)

Author keywords

Adverse drug reactions; Clinical trial; Pharmacovigilance

Indexed keywords

EID: 84915745090     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-695     Document Type: Review

References (91)

1. Aeries N: Consumer reporting of ADRs.WHO Drug Information 1995, 14:211–215.
2. Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M: What can we learn from parents about enhancing participation in Pharmacovigilance?British J Clin Pharmacol 2012,78(2):312–322.
3. Arora D: Pharmacovigilance obligations of the pharmaceutical companies in India.Indian J Pharmacol 2008, 40:13–16.
4. Bahri P, Tsintis P: Pharmacovigilance–related topics at the level of the International Conference on Harmonisation (ICH).Pharmacoepidemiol Drug Saf 2005, 14:377–387. 10.1002/pds.1043
5. Bates DW, Cullen DJ, Laird N: Incidence of adverse drug events and potential adverse drug events.JAMA 1995, 274:29–34. 10.1001/jama.1995.03530010043033
6. Beard K: Adverse reactions as a cause of hospital admission in the aged.Indian J Pharmacol 1992, 2:356–357.
7. Biswas P: Pharmacovigilance safety matters.Indian J Pharmacol 2008,7613(40):1–3.
8. Biswas P, Biswas A: Setting standards for proactive pharmacovigilance in India: The way forward.Indian J Pharmacol 2007, 39:124–128. 10.4103/0253-7613.33431
9. Brewer T, Colditz GA: Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.JAMA 1999, 281:824–829. 10.1001/jama.281.9.824
10. Carlo T, Francesco S: Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin.J Antimicrob Chemother 1978, 4:73–83.
11. Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, Caravati: Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management.Clin Toxicol 2007,45(2):95–131. 10.1080/15563650600907140
12. Ciorciaro C, Hartmann K, Kuhn M: Differences in the relative incidence of adverse drug reactions in relation to age, an evaluation of the spontaneous reporting system of SANZ.Journal Suisse de medicine 1998, 128:254–258.
13. Classen DC, Pestotnik SL, Evans RS: Adverse drug events in hospitalized patients.JAMA 1997,277(4):301–306. 10.1001/jama.1997.03540280039031
14. Cole M, Proctor GB, Trigoboff E: Adverse Drug Reaction Review: Evaluation of Concomitant Medications Effecting Blood Dyscrasias Associated with Clozapine. American Society of Health-System Pharmacists, Las Vegas December 6–10; 2009.
15. Delini SA, Mikkelsen H, Angst J: Therapeutic efficacy of antidepressants in agitated anxious depression–a meta-analysis of moclobemide studies.J Affect Disord 2007,35(2):21–30.
16. Doheny K: Reports of adverse drug effects up.Web MD Health News 2009, 6:1–2.
17. Douketis JD, Crowther M, Wells PS: A review on propofol and its drug and food interactions.Arch Intern Med 2007,45(10):167–176.
18. Faich GA: U.S. adverse drug reaction surveillance.Pharmacoepidemiol Drug Saf 1996,5(6):393–398. 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H
19. FDA: Early Communication about Safety of Lantus (insulin glargine). US Food and Drug Adminstration, Silver Spring, MD; 2009.
20. Fu H, Darroch JE, Henshaw SK, Kolb E: Measuring the extent of abortion underreporting in the 1995.Fam Plann Perspect 1998, 30:128–133. 138 10.2307/2991627
21. Gaudreault P, Temple AR, Lovejoy FH: The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison.Pediatrics 1982,70(4):566–569.
22. Gerritsen R, Faddegon H, Dijkers F, VanGrootheest K, Van Puijenbroek E: Effectiveness of pharmacovigilance training of general practitioners: a retrospective cohort study in the Netherlands comparing two methods.Drug Saf 2011, 34:755–762. 10.2165/11592800-000000000-00000
23. Goldman SA: Limitations and strengths of spontaneous reports data.Clinical Therapeutic 1998, 4:40–44.
24. Gor AP, Desai SV: Adverse drug reaction in the in patients of medicine department of a rural tertiary care teaching hospital and influence of pharmacovigilance in reporting ADR.Indian J Pharmacol 2008,40(1):37–40. 10.4103/0253-7613.40488
25. Gupta Y: Ensuring patient safety- launching the new pharmacovigilance programme of india.Pharma Times 2010,42(8):234–289.
26. Gupta P, Udupa A: Adverse drug Reaction Reporting and pharmacovigilance: knowledge, attitudes and perceptions amongst resident doctors.J Pharm Sci Res 2011,1459(2):1064–1069.
27. Hall M, Mc Cormack P, Arthurs N, Feely J: The spontaneous reporting of ADRs by nurses.British J ClinPharmacol 1995, 3:173–175.
28. Halpern GM: COX-2 inhibitors: a story of greed, deception and death.Inflammo Pharmacology 2005,13(4):419–425. 10.1163/156856005774415574
29. Hampton T: Experts point to lessons learned from controversy over rofecoxib safety.JAMA 2005, 293:413–414.
30. Harmark L, Van Grootheest AC: Pharmacovigilance: methods, recent developments and future perspective.European J ClinPharmacol 2008,64(6):743–752.
31. Haupt M, Jeste D: Mortality in elderly dementia patients treated with risperidone.J ClinPsychopharmacol 2006,26(6):566–570.
32. He Q, Luo X, Jin W, Huang Y, Reddy MV: Celecoxib and a novel COX-2 inhibitor ON09310 up regulate death receptor 5 expression via GADD153/CHOP.Inflammo Pharmacology 2005,13(4):419–425. 10.1163/156856005774415574
33. Herdiero MT, Figueiras A, Polonia J: Physians attitudes and adverse drug reaction reporting: a case control study in Portugal.Drug Saf 2005,28(9):825–833. 10.2165/00002018-200528090-00007
34. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions.Arch Intern Med 2005,165(10):1095–1106. 10.1001/archinte.165.10.1095
35. Holford NH: Clinical pharmacokinetics and pharmacodynamics of warfarin understanding the dose-effect relationship.Clin Pharmacokinet 1986,11(6):483–504. 10.2165/00003088-198611060-00005
36. Hornbuckle K, Wu HH, Fung MC: Evaluation of spontaneous adverse event reports by primary reporter - a 15-year review (1983 to 1997).Drug Inf J 1999, 33:1117–1124.
37. Huismen C, Ferreira CG, Broker LE: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line.Clin cancer Res 2002,8(2):596–606.
38. Hussein G, Bleidt B, Belding B: Recognition evaluation and reporting of adverse drug reactions.Clin Res Regul Aff 1999,16(3):91–107. 10.3109/10601339909007064
39. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity.Science 2010,327(5971):1345–1350. 10.1126/science.1177319
40. Jankovic J, beach J: Long term effects of tetrabenazine in hyperkinetic movement disorders.Neurology 1997,48(2):358–362. 10.1212/WNL.48.2.358
41. Jeetu G, Anusha G: Pharmacovigilance: a worldwide master key for drug safety monitoring.Journal Young Pharm 2010,2(3):315–316. 10.4103/0975-1483.66802
42. Joshi SR, Sapatnekar SM: The importance of pharmacovigilance. Geneva: World Health Organization, Pharmacovigilance in India: how safe are the new drugs? How sure are we?J Assoc Physicians Ind 2008,56(8):933–934.
43. Juntti PL, Neuvoren PJ: Drug related deaths in a university central hospital.Eur J ClinPharmacol 2002, 58:479–482.
44. Karch FE, Lasagna L: Towards the operational identification of adverse drug reactions.Clin Pharmacol Ther 1997, 21:247–254.
45. Kessler DA: Introducing Med Watch, using FDA form 3500, a new approach to reporting medication and device adverse effects and product problems.JAMA 1993, 269:2765–2778. 10.1001/jama.1993.03500210065033
46. Krumholz HM, Ross JS, Presler AH: What have we learnt from Vioxx?Br Med J 2007, 334:120–123. 10.1136/bmj.39024.487720.68
47. Kshirsagar N, Ferner R, Figueroa BA, Ghalib H, Lazdin J: Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis.Trans R Soc Trop Med Hyg 2011, 105:61–67. 10.1016/j.trstmh.2010.11.004
48. Kung HC, Hoyert DL, Xu JQ, Murphy SL: Increase in poisoning and methadone related effects; National Center for Health Statistics.Natl Vital Stat Rep 2008,56(10):8–15.
49. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients-a meta-analysis of prospective studies.JAMA 1998, 2:1200–1205.
50. Lisa A, Ladewski SM, Belknap JR, Nebeker OS: Dissemination of information on potentially fatal adverse drug reactions of drugs from 2000 to 2002: first results from the research on adverse drug events and reports project.J ClinOncol 2003,21(20):3859–3866. 10.1200/JCO.2003.04.537
51. Livio F, Renard D, Buclin T: Pharmacovigilance, a review.Med Suisse 2012, 8:116–119.
52. Lobo A, Germana M, Gerley J: Adverse drug reaction monitoring; support for pharmacovigilance at a tertiary care hospital in northern Brazil.BMC Pharmacol Toxicol 2013,78(3):1–7.
53. Marx J: Rosen’s Emergency Medicine: Concepts and Clinical Practice. Mosby Inc Mosby/Elsevier, Maryland Heights, Missouri; 2006:2242.
54. Michael S, Ma L: Fluoxetine and suicide rates suicide and the economy.J Pub Med 2006,3(11):501–503.
55. Minino AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M: Deaths: injuries.Natl Vital Stat Rep 2002,54(10):1–20.
56. Mishra H, Kumar V: Pharmacovigilance: current scenario in a tertiary care teaching Medical College in North India.Journal Pharmacovigilance 2013,1(2):1–4.
57. Mohammed A: Analysis of multiple risks involving the use of IV fentanyl.Patient Safe Advis 2012,9(4):122–129.
58. Moore N: The role of the clinical pharmacologist in the management of ADRs.Drug Saf 2001,24(1):1–7. 10.2165/00002018-200124010-00001
59. Murphy BM, Frigo LC: Development implementation and results of a successful ultidisciplinary adverse drug reaction reporting Program in a University Teaching Hospital.Hospital Pharm 1993, 28:1199–1240.
60. Muthiah NS, Elumalai M, Murali NP: HazraRamsundar: pharmacovigilance: a tool for health safety- review article.Indian J Multidiscip Dent 2012,2(1):374–376.
61. Naranjo CA, Busto U: A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther 1981, 30:239–245. 10.1038/clpt.1981.154
62. Nebeker JR, Barach P: Clarifying adverse drug events, a clinicians view.Ann Intern Med 2008, 12:87–112.
63. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med 2007, 356:2457–2471. 10.1056/NEJMoa072761
64. Olsson S: Pharmacovigilance training with focus on India.Ind J Pharmacol 2008,40(7):28–30.
65. Orlando M, Perkins CL: Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.Clin cancer Res 2002,8(2):596–606.
66. Palaian S, Mishra P, Shankar PR, Dubey AK, Bista D, Almeida R: Safety monitoring of drugs- where do we stand?Kathmandu Univ Med J 2006,4(13):119–120.
67. Panos T, Sintis P, La Mache E: CIOMS and ICH initiatives in pharmacovigilance and risk management overview and implications European agency for the evaluation of medicinal products.London, United Kingdom Drug Safety 2004,27(8):509–517.
68. Parthasarathi G, Karin Nyfort H, Nahata MC: Adverse Drug Reactions. A Textbook of Clinical Pharmacy Practice Essentials Concepts and Skills, vol 76. University Press, Hyderabad; 2007:84–102.
69. Pasero C: Fentanyl for acute pain management.J Perianesth Nurs 2005,20(4):279–284. 10.1016/j.jopan.2005.03.007
70. Pearson TF, Pittman D, Longley JM, Grapes T, Vigliotti DJ, Mullis SR: Factors associated with preventable adverse drug reactions.Am J Hosp Pharm 1994, 51:2268–2271.
71. Peng PW, Sandler AN: A review of the use of fentanyl analgesia in the management of acute pain in adults.Anesthesiology 1999,90(2):576–599. 10.1097/00000542-199902000-00034
72. Prommer E: The role of fentanyl in cancer-related pain.J Palliat Med 2009,12(10):947–954. 10.1089/jpm.2009.0051
73. Prosser TR, Kamysz PL: Multidisciplinary adverse drug reaction surveillance program.American J Hosp Pharm 1990, 47:1334–1339.
74. Purdue Pharma L.P. Stamford, CT: 06901–3431 2010 U.S. Patent Numbers 5,508,042; 6,488,963; 7,129,248; 7,674,799; 7,674,800 and 7,683,072. 2009.
75. Rahman SZ, Khan RA, Gupta V, Uddin M: Pharmacoenvironmentology - a component of pharmacovigilance.Environmental Health 2007,56(20):38–42.
76. Rao HP: Reporting of adverse drug reactions by consumers: rationale and potential. Pharmbit.Am J Hosp Pharm 2010,22(20):110.
77. Ravi Shankar P, Subish P, Mishra P, Dubey AK: Teaching pharmacovigilance to medical students and doctors.Indian J Pharmacol 2006,38(5):316–319. 10.4103/0253-7613.27698
78. Ravi Shankar P, Subish P, Mishra P, Dubey AK: Teaching Pharmacovigilance to Medical students and doctors.Educational Forum 2010,38(5):37–379.
79. Ravindra A, Vishal B: Pharmacovigilance: an overview.Int J Res Pharmacy Chemistry 2011,1(40):968–969.
80. Rawlins MD, Thompson JW: Mechanisms of Adverse Drug Reactions. In Textbook of Adverse Drug Reactions. 4th edition. Oxford: Oxford University press; 1981.
81. Rehan HS, Vasudev K, Tripathi CD: Adverse drug reaction monitoring: knowledge, attitude and practices of medical students and prescribers.Natl Med J India 2002,15(1):24–25.
82. Rishi RK, Patel RK, Bhandari A: Opinion of physicians towards adverse drug reactions reporting results of pilot study.J Commun Nutr Health 2012,1(1):25.
83. Rohilla A, Singh N, Kumar V, Sharma MK, Dahiya A, Kushnoor A: Pharmacovigilance: needs and objectives- review article.J Adv Pharm Technol Res 2012,2(4):201–205.
84. Santosh KC, Tragulpiankit P: Pharmacovigilance: an overeview. Department of Pharmacy, Faculty of Pharmacy Mahidol University.Journal of Pharmaceutical Sciences 2002, 21:23–146.
85. Schluter G: Ciprofloxacin: toxicological evaluation of additional safety data.Am J Med 1989,87(5):99–106.
86. Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA: Celecoxib analogs that lack. COX-2 inhibitory function: preclinical development of novel anticancer drugs.Expert Opin Investig Drugs 2003,17(2):197–208.
87. Shukla SS, Gidwani B, Pandey R, Rao SP, Singh V, Vyas: A importance of pharmacovigilance in Indian pharmaceutical industry – review article.Asian Pharma Online 2012, 5:2231–5659.
88. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.American J 2004, 109:2068–2073.
89. Surendra S, Dang A, Rataboli P: Pharmacovigilance and Pharmaco epidemiology.Indian J Pharm Sci 2010,72(1):96–102.
90. Thisted B, Krantz T, Stroom J, Sorensen M: Acute salicylate self-poisoning in 177 consecutive patients treated in ICU.Actaanaesthesiologica Scandinavica 1986,31(4):312–316.
91. Yadav S: Status of adverse drug reaction monitoring and pharmacovigilance in selected countries.Indian J Pharmacol 2008, 40:4–9.